Drug Profile
NMI 500
Alternative Names: NMI-500Latest Information Update: 18 Dec 2021
Price :
$50
*
At a glance
- Originator Nemucore Medical Innovations
- Class Antineoplastics; Radiopharmaceutical diagnostics; Small molecules; Taxanes
- Mechanism of Action Mitosis inhibitors; Tubulin modulators; Tubulin polymerisation promoters
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Ovarian cancer; Triple negative breast cancer
Most Recent Events
- 28 Feb 2019 No recent reports of development identified for phase-I development in Ovarian-cancer(Diagnosis) in USA (Parenteral)
- 28 Feb 2019 No recent reports of development identified for phase-I development in Ovarian-cancer(Second-line therapy or greater, Treatment-resistant) in USA (Parenteral)
- 28 Feb 2019 No recent reports of development identified for phase-I development in Triple negative Breast-cancer(Diagnosis) in USA (Parenteral)